Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huarui Zhang

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Nature Communications|June 24, 2020
Author Correction: HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritisChao Liang, Jie Li, Cheng Lu, et al.
Research (Washington, D.C.)|July 15, 2026
Dual-Mechanism Aptamer-Drug Complex Overcomes Paclitaxel Resistance in Ovarian Cancer via Structural Constraint and Telomerase InhibitionYuan Ma, Zefeng Chen, Xinyang Shen, et al.
Acta Pharmaceutica Sinica. B|July 15, 2026
AI-powered therapeutic aptamer drug discovery: Targeting the CT-domain of CTGF for duchenne muscular dystrophyShanshan Yao, Xin Yang, Meishen Ren, et al.
Molecular Therapy. Nucleic Acids|March 6, 2024
Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potentialAmu Gubu, Yuan Ma, Sifan Yu, et al.
Journal of Orthopaedic Translation|July 15, 2024
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectivesTao Xiaohui, Luyao Wang, Xin Yang, et al.
Nature Communications|July 22, 2022
Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formationYuanyuan Yu, Luyao Wang, Shuaijian Ni, et al.
Theranostics|August 15, 2022
Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta miceLuyao Wang, Yuanyuan Yu, Shuaijian Ni, et al.
Journal of Orthopaedic Translation|June 15, 2026
Blocking interaction of sclerostin loop3 with osteoblastic LRP4 counteracts bone loss without increasing arterial stiffness during mechanical unloadingLuyao Wang, Ning Zhang, Hewen Jiang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 24, 2025
Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective ActionLuyao Wang, Xiaohui Tao, Ning Zhang, et al.
Nature Communications|January 16, 2026
Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolismHewen Jiang, Xiaohui Tao, Sifan Yu, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Nature Communications|June 24, 2020
Author Correction: HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritisChao Liang, Jie Li, Cheng Lu, et al.
Research (Washington, D.C.)|July 15, 2026
Dual-Mechanism Aptamer-Drug Complex Overcomes Paclitaxel Resistance in Ovarian Cancer via Structural Constraint and Telomerase InhibitionYuan Ma, Zefeng Chen, Xinyang Shen, et al.
Acta Pharmaceutica Sinica. B|July 15, 2026
AI-powered therapeutic aptamer drug discovery: Targeting the CT-domain of CTGF for duchenne muscular dystrophyShanshan Yao, Xin Yang, Meishen Ren, et al.
Molecular Therapy. Nucleic Acids|March 6, 2024
Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potentialAmu Gubu, Yuan Ma, Sifan Yu, et al.
Journal of Orthopaedic Translation|July 15, 2024
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectivesTao Xiaohui, Luyao Wang, Xin Yang, et al.
Nature Communications|July 22, 2022
Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formationYuanyuan Yu, Luyao Wang, Shuaijian Ni, et al.
Theranostics|August 15, 2022
Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta miceLuyao Wang, Yuanyuan Yu, Shuaijian Ni, et al.
Journal of Orthopaedic Translation|June 15, 2026
Blocking interaction of sclerostin loop3 with osteoblastic LRP4 counteracts bone loss without increasing arterial stiffness during mechanical unloadingLuyao Wang, Ning Zhang, Hewen Jiang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 24, 2025
Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective ActionLuyao Wang, Xiaohui Tao, Ning Zhang, et al.
Nature Communications|January 16, 2026
Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolismHewen Jiang, Xiaohui Tao, Sifan Yu, et al.
Pageof 5